Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1010

Sort by

Sort Order Select

Journal Articles

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

Hermann Einsele, Per Ljungman, Michael Boeckh

Blood (2020) 135 (19): 1619–1629.

https://doi.org/10.1182/blood.2019000956

Published: 2020

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Epidemiology of Post-Transplant Lymphoproliferative Disorders in Children with Solid Organ Transplant over 34 Years of a Single Center Experience

Marta Rojas Vasquez, MD FRCPC, Anthea Peters, MSc, MD FRCPC, Raymond Lai, MD PhD FRCP, Curtis Mabilangan, MSc, Burton Catherine, MD FRCPC, Jutta Preiksaitis, MDFRCPC

Blood (2019) 134 (Supplement_1): 1602.

https://doi.org/10.1182/blood-2019-125344

Published: 2019

Journal Articles

Integrative Study of EZH2 Mutational Status, Copy Number, Protein Expression and H3K27 Trimethylation in AML/MDS Patients

Julia Stomper, Ruth Meier, Tobias Ma, Dietmar Pfeifer, Annette Schmitt-Graeff, Michael Lübbert

Blood (2019) 134 (Supplement_1): 1422.

https://doi.org/10.1182/blood-2019-128231

Published: 2019

Journal Articles

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Amy Wang, MD MPH, Justin Kline, MD, Wendy Stock, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Peter A. Riedell, MD, Michael R. Bishop, MD, Hongtao Liu, MD PhD

Blood (2019) 134 (Supplement_1): 1956.

https://doi.org/10.1182/blood-2019-123887

Published: 2019

Journal Articles

Efficacy of Allogeneic Hematopoietic Cell Transplantation (HCT) in Sickle Cell Disease: Results of a Systematic Review/Meta-Analysis

Madiha Iqbal, MBBS, Tea Reljic, MPH, Ernesto Ayala, MD, Hemant S. Murthy, MD, Ambuj Kumar, MD MPH, Mohamed A Kharfan-Dabaja, MDMBA

Blood (2019) 134 (Supplement_1): 2106.

https://doi.org/10.1182/blood-2019-124955

Published: 2019

Journal Articles

The UK Experience of Renal Transplantation in AL Amyloidosis

Oliver C Cohen, MB BS, BSc, FRCPath, Faye Sharpley, MBBChir, MA, MRCP, MSc, Julian Gillmore, Helen Lachmann, Shameem Mahmood, Sajitha Sachchithanantham, Carol Whelan, Ana Martinez De Azcona Naharro, Marianna Fontana, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (Supplement_1): 2206.

https://doi.org/10.1182/blood-2019-128443

Published: 2019

Journal Articles

Full Donor Chimerism after Allografts for Myelofibrosis: The Role of Conditioning Regimen

Patrizia Chiusolo, Sabrina Giammarco, MD PhD, Teresa Lamparelli, Lucia Casarino, Monica Rossi, Alida Dominietto, MD, Anna Maria Raiola, MD, Francesca Gualandi, Carmen Di Grazia, MD, Silvia Betti, MD PhD, Federica Sorà, MD, Elena Rossi, MD PhD, Luciana Teofili, MD, Simona Sica, MD, Andrea Bacigalupo, MD, Emanuele Angelucci, MD

Blood (2019) 134 (Supplement_1): 4490.

https://doi.org/10.1182/blood-2019-126711

Published: 2019

Journal Articles

Poor-Risk AML with Complex, Monosomal Karyotype: In Vivo Therapeutic Efficacy of Decitabine (DAC) in Patient-Derived Xenograft (PDX) Mouse Models

Gabriele Greve, PhD, Julia Schüler, DVM, Eva Oswald, PhD, Michael Lübbert

Blood (2019) 134 (Supplement_1): 2644.

https://doi.org/10.1182/blood-2019-126514

Published: 2019

Journal Articles

Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia

Ghayas C. Issa, MD, Christopher B. Benton, MD, Vakul Mohanty, PhD, Yifei Shen, PhD, Zoe Alaniz, Feng Wang, PhD, P. Andrew Futreal, PhD, Wei Wang, MD PhD, Jeffrey L. Jorgensen, MD PhD, Nicholas Navin, PhD, Marina Y Konopleva, MD PhD, Ken Chen, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2717.

https://doi.org/10.1182/blood-2019-130540

Published: 2019

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Blood (2019) 134 (Supplement_1): 2926.

https://doi.org/10.1182/blood-2019-125740

Published: 2019

Journal Articles

Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience

Zachary D. Epstein-Peterson, MD, Paola Ghione, MD, Alison J. Moskowitz, MD, Parastoo B. Dahi, MD, Ahmet Dogan, MD PhD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, Miguel-Angel Perales, MD, Doris M Ponce, MD, David J. Straus, MD, Andrew D. Zelenetz, MD PhD, Craig S. Sauter, MD, Steven M. Horwitz, MD

Blood (2019) 134 (Supplement_1): 2850.

https://doi.org/10.1182/blood-2019-125376

Published: 2019

Journal Articles

Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD)

Amy E. DeZern, MD, Marianna Zahurak, MS, Javier Bolanos-Meade, MD, Richard J. Jones, MD

Blood (2019) 134 (Supplement_1): 3320.

https://doi.org/10.1182/blood-2019-122762

Published: 2019

Journal Articles

The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis

Lorenz Selberg, Peter Stadtherr, Sascha Dietrich, MD, Thomas Luft, MD PhD, Andrea Bondong, Ute Hegenbart, MD, Julia Meissner, MD, Nora Liebers, Michael Schmitt, MD, Carsten Mueller-Tidow, MD, Peter Dreger

Blood (2019) 134 (Supplement_1): 3328.

https://doi.org/10.1182/blood-2019-128352

Published: 2019

Journal Articles

Hematopoietic Mononuclear Cell Transplant with Minimal Gvhd in up to Completely Mismatched Unrelated Recipients

Suzanne T Ildstad, MD

Blood (2019) 134 (Supplement_1): 3243.

https://doi.org/10.1182/blood-2019-130943

Published: 2019

Journal Articles

Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection

Patrice Chevallier, MD, Pierre Peterlin, Alice Garnier, MD, Amandine Le Bourgeois, MD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Cyrille Touzeau, MD, Thomas Gastinne, MD, Anne Lok, MD, Benoit Tessoulin, MD PhD, Yannick Le Bris, PharmD, Marie C Bene, PharmSci, PhD, Steven Le Gouill, MD PhD, Philippe Moreau, MD, Thierry Guillaume, MD PhD

Blood (2019) 134 (Supplement_1): 4528.

https://doi.org/10.1182/blood-2019-125787

Published: 2019

Journal Articles

Combination Therapy of Allogeneic HSCT and In Vivo Activated iNKT Cells Prevents Acute Gvhd While Augmenting GVL Effect

Samuel Zeng, Qingxiao Song, MD PhD, Shanshan Tang, Xi Wang, PhD, Yuchen Wang, PhD, Defu Zeng, MD PhD, Lili Yang, PhD

Blood (2019) 134 (Supplement_1): 4439.

https://doi.org/10.1182/blood-2019-130826

Published: 2019

Journal Articles

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Maria Queralt Salas, MD, Shiyi Chen, Wilson Lam, MD, David Loach, MD, Fotios V. Michelis, MD PhD, Zeyad Al-Shaibani, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Rajat Kumar, MD, Jonas Mattsson, MD, Arjun Law, MDDM

Blood (2019) 134 (Supplement_1): 4590.

https://doi.org/10.1182/blood-2019-126236

Published: 2019

Journal Articles

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β-Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy

Pietro Merli, MD, Annalisa Ruggeri, MD, Mattia Algeri, MD, Giuseppina Li Pira, PhD, Giulia Ceglie, MD, Katiana Gruppioni, MPH, Sanjeev Kommera, MS, Jenfue Maa, PhD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 969.

https://doi.org/10.1182/blood-2019-123440

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

AL patients don’t dare go without dara

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Epidemiology of Post-Transplant Lymphoproliferative Disorders in Children with Solid Organ Transplant over 34 Years of a Single Center Experience

Integrative Study of EZH2 Mutational Status, Copy Number, Protein Expression and H3K27 Trimethylation in AML/MDS Patients

Unexpected Toxicities When Nivolumab Was Given after Allogeneic Stem Cell Transplantation

Efficacy of Allogeneic Hematopoietic Cell Transplantation (HCT) in Sickle Cell Disease: Results of a Systematic Review/Meta-Analysis

The UK Experience of Renal Transplantation in AL Amyloidosis

Full Donor Chimerism after Allografts for Myelofibrosis: The Role of Conditioning Regimen

Poor-Risk AML with Complex, Monosomal Karyotype: In Vivo Therapeutic Efficacy of Decitabine (DAC) in Patient-Derived Xenograft (PDX) Mouse Models

Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience

Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD)

The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis

Hematopoietic Mononuclear Cell Transplant with Minimal Gvhd in up to Completely Mismatched Unrelated Recipients

Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection

Combination Therapy of Allogeneic HSCT and In Vivo Activated iNKT Cells Prevents Acute Gvhd While Augmenting GVL Effect

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β-Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only